CN1919241A - Chinese medicinal preparation for treating cardiovascular and cerebrovascular disease - Google Patents
Chinese medicinal preparation for treating cardiovascular and cerebrovascular disease Download PDFInfo
- Publication number
- CN1919241A CN1919241A CN 200510014840 CN200510014840A CN1919241A CN 1919241 A CN1919241 A CN 1919241A CN 200510014840 CN200510014840 CN 200510014840 CN 200510014840 A CN200510014840 A CN 200510014840A CN 1919241 A CN1919241 A CN 1919241A
- Authority
- CN
- China
- Prior art keywords
- extract
- salviae miltiorrhizae
- radix salviae
- tanshinone
- phenolic acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 18
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 14
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title abstract description 27
- 239000000284 extract Substances 0.000 claims abstract description 264
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 claims abstract description 240
- 229930183118 Tanshinone Natural products 0.000 claims abstract description 154
- 229930182470 glycoside Natural products 0.000 claims abstract description 78
- 150000002338 glycosides Chemical class 0.000 claims abstract description 78
- 239000000203 mixture Substances 0.000 claims abstract description 76
- 229930182490 saponin Natural products 0.000 claims abstract description 15
- 150000007949 saponins Chemical class 0.000 claims abstract description 15
- 235000017709 saponins Nutrition 0.000 claims abstract description 15
- 239000002253 acid Substances 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 135
- 150000007965 phenolic acids Chemical class 0.000 claims description 94
- 235000009048 phenolic acids Nutrition 0.000 claims description 93
- 239000003814 drug Substances 0.000 claims description 84
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 82
- 241000180649 Panax notoginseng Species 0.000 claims description 82
- -1 hydroxypropyl Chemical group 0.000 claims description 53
- 238000000605 extraction Methods 0.000 claims description 44
- 239000000843 powder Substances 0.000 claims description 39
- 239000000706 filtrate Substances 0.000 claims description 29
- 239000012567 medical material Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 238000001035 drying Methods 0.000 claims description 25
- 238000003756 stirring Methods 0.000 claims description 24
- 239000006187 pill Substances 0.000 claims description 23
- 238000001914 filtration Methods 0.000 claims description 20
- 238000010828 elution Methods 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 239000011347 resin Substances 0.000 claims description 18
- 229920005989 resin Polymers 0.000 claims description 18
- 229920006395 saturated elastomer Polymers 0.000 claims description 18
- 239000003480 eluent Substances 0.000 claims description 17
- 238000004321 preservation Methods 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 16
- 238000010438 heat treatment Methods 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 11
- 238000002844 melting Methods 0.000 claims description 10
- 230000008018 melting Effects 0.000 claims description 10
- 229940057995 liquid paraffin Drugs 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 238000011010 flushing procedure Methods 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 7
- 108010059892 Cellulase Proteins 0.000 claims description 6
- 239000003957 anion exchange resin Substances 0.000 claims description 6
- 229940106157 cellulase Drugs 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 6
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 5
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 5
- 240000007164 Salvia officinalis Species 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 5
- 239000003456 ion exchange resin Substances 0.000 claims description 5
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 5
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 5
- 230000004087 circulation Effects 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000013461 design Methods 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 235000017276 Salvia Nutrition 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 8
- 201000006474 Brain Ischemia Diseases 0.000 abstract description 6
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract description 6
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 abstract description 5
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 5
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 239000010669 rosewood oil Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 49
- 241001465754 Metazoa Species 0.000 description 14
- 241000700159 Rattus Species 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 10
- 238000004108 freeze drying Methods 0.000 description 8
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 6
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 6
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 5
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000003657 middle cerebral artery Anatomy 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 description 3
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000003194 forelimb Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 229930183842 salvianolic acid Natural products 0.000 description 3
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 3
- 229920002545 silicone oil Polymers 0.000 description 3
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000053227 Themus Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical group Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 235000005412 red sage Nutrition 0.000 description 2
- 210000001562 sternum Anatomy 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000202721 Guihaia Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000004298 cerebral vein Anatomy 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- SBNFWQZLDJGRLK-UHFFFAOYSA-N phenothrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000003582 temporal bone Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Group | Dosage (mg/kg) | Number of animals | Nervous symptoms scoring in 6 hours | Nervous symptoms scoring in 24 hours |
The Folium Notoginseng glycoside extract model group of the salvianolic acid extract embodiment one of the tanshinone extract embodiment one of the Chinese medicine composition embodiment one of the Chinese medicine composition embodiment two of embodiment one | 20 20 20 20 20 | 10 10 10 10 10 10 | 2.27±0.49** #&@ 2.34±0.38** #&@ 2.82±0.38* 2.76±0.47* 2.81±0.44* 3.23±0.41 | 2.03±0.41** #&@ 2.02±0.38** #&@ 2.55±0.48* 2.48±0.43* 2.56±0.43* 3.01±0.48 |
Group | Dosage (mg/kg) | Number of animals | Infraction heavily accounts for full brain % | Infraction heavily accounts for half brain % |
The Folium Notoginseng glycoside extract model group of the salvianolic acid extract embodiment one of the tanshinone extract embodiment one of the Chinese medicine composition embodiment one of the Chinese medicine composition embodiment two of embodiment one | 20 20 20 20 20 | 10 10 10 10 10 10 | 2.58±0.62** #&@ 2.56±0.65** #&@ 3.41±0.73* 3.35±0.84* 3.34±0.81* 4.33±0.76 | 4.61±1.35** #&@ 4.64±1.28** #&@ 6.28±1.68* 6.12±1.73* 6.29±1.65* 8.21±1.54 |
Group | Dosage (mg/kg) | Number of animals | Infarcted region/ventricle (%) | Infarcted region/heart (%) |
The Folium Notoginseng glycoside extract model group of the salvianolic acid extract embodiment two of the tanshinone extract embodiment two of the Chinese medicine composition embodiment two of the Chinese medicine composition embodiment two of embodiment one | 20 20 20 20 20 | 10 10 10 10 10 10 | 17.76±6.57** #&@ 17.81±6.79** #&@ 26.12±7.24* 24.67±7.64* 26.11±7.89* 34.35±7.54 | 15.66±4.80** #&@ 14.72±4.55** #&@ 20.12±4.37* 19.34±4.81* 20.82±4.12* 25.62±5.59 |
Group | Dosage (mg/ml) | Coronary flow value added (ml/min) | Heart rate attenuating value (inferior/min) |
The Folium Notoginseng glycoside extract of the Radix Salviae Miltiorrhizae total phenolic acids extract embodiment two of the tanshinone extract embodiment two of the Chinese medicine composition embodiment two of the Chinese medicine composition embodiment two of embodiment one | 20 20 20 20 20 | 10.28±1.54 **##@@ 10.34±1.82 **##@@ 7.31±1.24 7.65±1.33 7.26±1.43 | 19±11* #& 19±11* #@ 9±5 10±5 10±5 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005100148404A CN1919241B (en) | 2005-08-24 | 2005-08-24 | Chinese medicinal preparation for treating cardiovascular and cerebrovascular disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005100148404A CN1919241B (en) | 2005-08-24 | 2005-08-24 | Chinese medicinal preparation for treating cardiovascular and cerebrovascular disease |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1919241A true CN1919241A (en) | 2007-02-28 |
CN1919241B CN1919241B (en) | 2011-06-08 |
Family
ID=37777177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005100148404A Expired - Fee Related CN1919241B (en) | 2005-08-24 | 2005-08-24 | Chinese medicinal preparation for treating cardiovascular and cerebrovascular disease |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1919241B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102028742A (en) * | 2009-09-29 | 2011-04-27 | 天津天士力现代中药资源有限公司 | Drug for treating coronary heart disease and extraction method thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1349818A (en) * | 2001-10-24 | 2002-05-22 | 沈阳药科大学 | Effective part group in red sage mixture and its delayed release prepn. medicinal use and prepn process |
-
2005
- 2005-08-24 CN CN2005100148404A patent/CN1919241B/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102028742A (en) * | 2009-09-29 | 2011-04-27 | 天津天士力现代中药资源有限公司 | Drug for treating coronary heart disease and extraction method thereof |
CN102028742B (en) * | 2009-09-29 | 2013-09-04 | 天津天士力现代中药资源有限公司 | Drug for treating coronary heart disease and extraction method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1919241B (en) | 2011-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100339085C (en) | Combination of Chinese traditional medicine for curing cardiovascular and cerebrovascular diseases | |
CN1600318A (en) | Combination of Chinese traditional medicine for curing cardiovascular diseases and cerebrovascular disease | |
CN1857352A (en) | Notoginseng medicine composition for treating cardiac and cerebral vascular diseases | |
CN1919248A (en) | Traditional Chinese medicinal formulation for treating cardiovascular and cerebrovascular disease | |
CN1919240A (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases | |
CN1919239A (en) | Traditional medicine composition for treating cardiovascular and cerebrovascular diseases | |
CN1919238A (en) | Medicine for treating cardiovascular and cerebrovascular disease | |
CN1919247A (en) | Chinese medicine for treating cardiovascular and cerebrovascular disease | |
CN1919252A (en) | Medicine for treating cardiovascular and cerebrovascular disease | |
CN1919235A (en) | Cardiac and cerebral vascular disease treating pharmaceutical composition | |
CN1919242A (en) | Traditional Chinese medicine composition for treating cardiac and cerebral vascular disease | |
CN1919253A (en) | Cardiac and cerebral vascular disease treating medicinal composition | |
CN1853688A (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and ischemic apoplexia and making method thereof | |
CN1919249A (en) | Chinese traditional medicine for treating cardiovascular and cerebrovascular disease | |
CN1919241A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular disease | |
CN1919237A (en) | Medicine for treating cardiovascular and cerebrovascular diseases | |
CN1853689A (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and making method thereof | |
CN1582952A (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
CN1919250A (en) | Traditional Chinese medicinal formulation for treating cardiovascular and cerebrovascular disease | |
CN1919236A (en) | Medicine for treating cardiovascular and cerebrovascular diseases | |
CN1919244A (en) | Chinese traditional medicine for treating cardiovascular disease | |
CN1919243A (en) | Traditional medicine composition for treating cardiovascular and cerebrovascular diseases | |
CN1919251A (en) | Traditional Chinese medicine composition for treating cardiac vascular disease | |
CN1582946A (en) | Use of centellosic acid derivative in preparation of medicines for diseases of cardio-cerebral blood vessels | |
CN1965849A (en) | Composition extracted from Chinese medicinals for treating coronary heart disease and method for preparing ingredients thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20070608 Address after: Tianjin City Hedong District of Beichen Puji No. 2 in the modern Chinese medicine city Applicant after: Tianjin Tianshili Pharmaceutical Co., Ltd. Address before: The white road of Beichen science and Technology Park in Beichen District of Tianjin City Xinyi Liaohe Road No. 1 Applicant before: Tianshili Modern Traditional Chinese Medicine Research & Devleopment Co., Ltd., |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin city Beichen District Puji Hedong No. 2 in the modern Chinese medicine city Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin city Beichen District Puji Hedong No. 2 in the modern Chinese medicine city Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin city Beichen District Puji Hedong No. 2 in the modern Chinese medicine city Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin city Beichen District Puji Hedong No. 2 in the modern Chinese medicine city Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110608 Termination date: 20190824 |